

Independent Scientific Research Supports AFFIRMATIVhealth's Alzheimer's Therapy

Independent scientific research supports AFFIRMATIVhealth's treatment and prevention of Alzheimer's disease and dementia.



SONOMA, CALIFORNIA, UNITED STATES, May 9, 2017 /EINPresswire.com/ --CONTACT: Denise M Kalos Chief Operating Officer <u>AFFIRMATIVhealth</u>, PLLC 707-800-2302

dmkalos@affirmativhealth.com

٢

The large volume of evidence continually being presented by independent research groups supports the strategy of AFFIRMATIVhealth's RE:mind program to mitigate cognitive decline with aging." Dr. Brain Kennedy, Scientific Director of AFFIRMATIVhealth FOR IMMEDIATE RELEASE

Independent scientific research supports AFFIRMATIVhealth's treatment and prevention of Alzheimer's disease and dementia.

April 12, 2017 Novato/Sonoma, CA This March PLOS, a nonprofit publisher, innovator and advocacy organization based in San Francisco, published a PLOS Medicine Special Issue highlighting a broad range of new dementia research. Each independent paper presented in this edition of PLOS Medicine offers compelling evidence that supports the

personalized care and multi-factor treatment plan offered through the AFFIRMATIVhealth's cognitive improvement program, RE:mind Immersion.

Alzheimer's Disease International (ADI) estimates there will be over 131.5 million people living with dementia by 2050. This startling projected growth of dementia cases, as well as the associated global economic impact motivated PLOS Medicine to dedicate this special issue to dementia. The research papers published in this PLOS Medicine Special Issue address, and hope to offer greater understanding on a spectrum of issues within the discussion of dementia and the Alzheimer's disease. Among many fascinating findings presented, researchers found that genetic analysis allows for better personal risk assessment of the Alzheimer's disease and an improved therapeutic strategy to combat the disease. One paper also provides evidence that older people who make changes in their diet, exercise more, and engage in more socially oriented and mentally stimulating activities can improve and maintain their mental health. The importance of creating better consistent and on-going support for dementia patients and their caregivers is another significant issue discussed. All papers presented in this PLOS Medicine Special Issue reaffirm the complexity of Alzheimer's disease and dementia, but also assert that there is more and more evidence suggesting that each individual can take proactive measures to protect and improve their cognitive health.

(http://collections.plos.org/dementia)

Similar to PLOS Medicine papers on dementia, AFFIRMATIVhealth's licensed intellectual property from the Buck Institute for Research on Aging, includes extensive research on brain health which has also lead them to find an abundance of evidence that lifestyle modifications, metabolic optimization, and other non-pharmaceutical approaches can provide substantial benefits for sufferers of early Alzheimer's and cognitive decline, with results that are in many ways more impressive than traditional approaches. They also found that each person has a unique combination of factors contributing to their cognitive decline which emphasizes the importance of individualized treatment plans. From this research, the <u>RE:mind program</u> was born to put the data into action and offer more than just hope, but an actual plan to save the memories and lives of those suffering from early Alzheimer's and dementia. The RE:mind program includes testing and medical data capture, baseline protocol, 4-day retreat, 3 months follow-up coaching, and updated protocol.

Dr. Brain Kennedy, Scientific Director of AFFIRMATIVhealth, stated "Traditional medicine has yet to prove effective when dealing with Alzheimer's and other types of dementia. As with other ongoing research on aging and cognitive wellness, the papers in this special edition of PLOS Medicine present the significant promise that alternative holistic strategies including lifestyle, diet, nutraceuticals and drugs are now available. The large volume of evidence continually being presented by independent research groups supports the strategy of AFFIRMATIVhealth's RE:mind program to mitigate cognitive decline with aging."

The next RE:mind Program is June 26-29th 2017 in Sonoma, CA. Limited space is still available. If you or someone you know may benefit from attending the retreat, please contact us directly at 707.800.2302, or email us at: remind@affirmativhealth.com.

About AFFIRMATIVhealth: AFFIRMATIVhealth empowers to those affected by Alzheimer's disease and their caregivers with education, advocacy, and hope. We seek to bring the latest health-conscious science to those with early stage cognitive decline or genetic predispositions for these disorders. We do this by educating and supporting these individuals, utilizing the most recent scientific knowledge on diet, lifestyle and other key factors for maximizing brain health and fighting the effects of neurodegenerative diseases. (https://affirmativhealth.com)

Denise KALOS AFFIRMATIVhealth 707-800-2302 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.